Gilead Sciences’ seladelpar gains support as PBC treatment in Europe
In a significant milestone for liver disease therapeutics, Gilead Sciences, Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the ... Read More
Dr. Reddy’s joins forces with Gilead Sciences to launch HIV drug Lenacapavir in India and 120 countries
In a historic development for HIV treatment worldwide, Dr. Reddy's Laboratories has announced a new partnership with Gilead Sciences to manufacture and commercialize a revolutionary ... Read More
Unbelievable cure: German man beats HIV after revolutionary treatment
In a groundbreaking development in the fight against HIV, a 60-year-old German man has been declared free of the virus, marking only the seventh such ... Read More
Gilead and Arcus announce significant advancement in metastatic colorectal cancer treatment with etrumadenant plus zimberelimab regimen
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have released promising new data from their collaborative study, ARC-9, during an oral session ... Read More
Gilead Sciences completes $4.3bn acquisition of CymaBay Therapeutics to enhance liver disease portfolio
Gilead Sciences, Inc. (Nasdaq: GILD) has officially announced the successful acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for a staggering $4.3 billion, a move that ... Read More
Gilead Sciences to acquire CymaBay Therapeutics to enhance liver disease portfolio
In a significant move within the biopharmaceutical industry, Gilead Sciences, Inc. (Nasdaq: GILD) has confirmed its acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for a ... Read More
Gilead Sciences invests $320m in Arcus Biosciences to accelerate cancer treatment innovations
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have announced a significant amendment to their collaboration agreement, accompanied by a substantial $320 ... Read More
Strides Pharma subsidiary gains FDA approval for EET tablets
Strides Pharma Science Limited has announced a significant achievement, with its wholly-owned subsidiary, Strides Pharma Global Pte. Limited in Singapore, receiving approval from the United ... Read More
Gilead’s EVOKE-02 study of Trodelvy, KEYTRUDA combo shows promise in NSCLC
Gilead Sciences, Inc. announced early data showcasing promising clinical activity of Trodelvy in combination with Merck's KEYTRUDA for first-line treatment of metastatic non-small cell lung ... Read More
Gilead’s Trodelvy gains EC approval as new hope for metastatic breast cancer patients
In a significant advancement for cancer treatment, the European Commission (EC) has approved Gilead Sciences' Trodelvy (sacituzumab govitecan) for the treatment of adult patients suffering ... Read More